ALK and neoplasm: Patients who carried driver gene mutations (EGFR or BRAF mutations or ALK/ROS1 rearrangements), who received ICIs as neoadjuvant treatment or less than two cycles of ICIs, who were lost to follow-up, and who did not complete the tumor response assessment were excluded from the study.